1.53 USD
↘ 0.02 (1.29%)AT CLOSE (11:59 AM EDT)
Geron Corp
GERNNASDAQ • USD
1.54
↗ 0.01 (0.92%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
1.54
↗ 0.01 (0.92%)
Market: CLOSED
Geron Corp (GERN) trades at $1.54 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place GERN at a fair price relative to peers.
Technical & fundamental data as of Aug 26, 2026.
Open?$1.58
High?$1.58
Low?$1.50
Prev. Close?$1.55
Volume?9.1M
Avg. Volume?9.9M
VWAP?$1.52
Rel. Volume?0.92x
Bid / Ask
Bid?$1.54 × 1.8K
Ask?$1.55 × 6.0K
Spread?$0.01
Midpoint?$1.55
Valuation & Ratios
Market Cap?983.0M
Shares Out?642.5M
Float?626.7M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?4.50
EPS?-$0.11
Dividend?0.00%
Ex-Dividend?N/A
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Themes
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?20
Short Sent.?40
Piotroski F-Score?2/9Weak
Altman Z-Score?-2.04Distress
Confidence?66%Moderate
Short InterestHigh
Short % of Float?12.86%High
Short Interest?80.6M
Days to Cover?5.8
Free Float626.7M
Avg Daily Volume13.9M
Settlement Date2026-08-14
Financial Health
Current Ratio?6.92Strong
Quick Ratio?5.16Strong
Cash Ratio?0.89Adequate
Debt/Equity?1.14Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score75/100
P/E?N/A▾
P/B?4.50FAIR▾
Peers100
S&P40
P/S?4.81FAIR▾
Peers100
S&P30
P/FCF?N/A▾
EV/EBITDA?-33.6CHEAP▾
Peers100
S&P97
EV/Sales?5.72FAIR▾
Peers50
S&P30
Returns & Efficiency
ROE?-30.9%WEAK▾
Peers50
S&P6
ROA?-13.0%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-114762000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day